Education and Training
A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception
The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: LNG20
- drug: Mirena
Eligibility
Inclusion Criteria:
- Healthy women requesting contraception
- 16-35 years old
- Cohort 36-45 years old
- Sexually active
Exclusion Criteria:
- Currently pregnant, pregnant within 4 weeks prior to study entry or planning pregnancy
within 24 months of study entry
- Currently breastfeeding
- Current persistent, abnormal vaginal bleeding
Ages Eligible for Study
16 Years - 45 Years
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7826
I'm interested